Post-Treatment Kinetics of BCNU in a 9L Rat Brain Tumor Model

概要

論文の詳細を見る
After in vivo treatment with BCNU at 13.3 mg/kg, the dose lethal to 10% (LD_<10>), rats implanted with 9L brain tumors exhibited an increased life span (ILS) of 56%. The growth fraction (GF) of treated tumors, as measured by fractionated doses of ^3H-thymidine administered over 0 h, decreased for the first 2 to 10 days post-treatment, then increased and overshot the baseline (though by no more than 10%) by Day 21. A second treatment with a LD_<10>of BCNU either 5, 10, or 14 days after the initial treatment increased the ILS to 126-128% and resulted in long-term survival (ILS>300%) in 20% to 30% of animals, but did not produce a remarkable change in GF beyond that resulting from the initial treatment. Histological examinations revealed increased numbers of giant cells 2 to 6 days after the initial treatment; however, mitosis decreased immediately following treatment and remained low for the next 8 days. These results imply that (in this animal model, at least) a cell cycle non-specific (CCNS) drug is more effective as a second treatment after initial treatment with a CCNS drug than is a cell cycle specific one.
日本脳神経外科学会の論文
1981-01-15